2017 Press Releases

Keyword Search
 
DateTitle  
16-Nov-2017Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – November 16, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Nov. 16, 2017-- Regulatory News: Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol : ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.co... 
 Printer Friendly Version
15-Nov-2017ERYTECH Announces Commencement of Trading of ADSs on Nasdaq and Full Exercise of Underwriters’ Option, Bringing Gross Proceeds of Global Offering to $144 Million
Base deal of $125 million in gross proceeds from specified categories of specialized investors closed on November 14, 2017. Announced full exercise of underwriters’ option to purchase additional American Depositary Shares (ADSs) and Ordinary Shares, with closing expected to take place on or about November 16, 2017. Will add approximately $19 million in additional gross proceeds for total of $144 million in gross proceeds. ... 
 Printer Friendly Version
14-Nov-2017ERYTECH to Webcast Presentation at Jefferies 2017 London Healthcare Conference
LYON, France--(BUSINESS WIRE)--Nov. 14, 2017-- Regulatory News: ERYTECH Pharma (Nasdaq and Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen, Chairman and Chief Executive Officer, will present at the Jefferies Global Healthcare on November 15th, 2017 at the Waldorf Hilton Hotel (Aldwych) in London,... 
 Printer Friendly Version
13-Nov-2017ERYTECH to Host Third Quarter 2017 Conference Call and Business Update on November 14, 2017
LYON, France--(BUSINESS WIRE)--Nov. 13, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (Nasdaq and Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a Third Quarter 2017 conference call and webcast on Tuesday, November 14, 2017, at 2:30 PM CET/8:30 AM EST to discuss operational... 
 Printer Friendly Version
10-Nov-2017Erytech Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
LYON, France--(BUSINESS WIRE)--Nov. 10, 2017-- Regulatory News: NOT FOR DISTRIBUTION IN AUSTRALIA, CANADA OR JAPAN ERYTECH Pharma (Paris:ERYP) (Euronext Paris: ERYP) (“ERYTECH” or “the Company”) announces trading resumption of its ordinary shares on Euronext Paris as from 4:00pm CET. Trading in the ordinary shares of ERYTECH Pharma was suspended at the request of the Company on November 10, 2017 from 9:00 am CET in ... 
 Printer Friendly Version
10-Nov-2017ERYTECH Announces Pricing of Global Offering and Approval to List on Nasdaq Global Select Market
LYON, France--(BUSINESS WIRE)--Nov. 10, 2017-- Regulatory News: NOT FOR DISTRIBUTION IN AUSTRALIA, CANADA AND JAPAN ERYTECH Pharma (Paris:ERYP) ("ERYTECH" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the pricing of its global offering to specified categories of investors of an aggregate of 5,374,033 ... 
 Printer Friendly Version
10-Nov-2017ERYTECH Announces Trading Suspension of Its Ordinary Shares on Euronext Paris
LYON, France--(BUSINESS WIRE)--Nov. 10, 2017-- Regulatory News: NOT FOR DISTRIBUTION IN AUSTRALIA, CANADA OR JAPAN Trading in the ordinary shares of ERYTECH Pharma (Euronext Paris: ERYP) (“ERYTECH” or “the Company”) (Paris:ERYP) (ADR:EYRYY), was suspended at the request of the Company on November 10, 2017 from 9:00 am CET in connection with its previously announced global offering in order to allow for the confirmation of allocat... 
 Printer Friendly Version
06-Nov-2017ERYTECH Reports Third Quarter 2017 Financial Results and Provides Business Update
Presented full results of Phase 2b trial of eryaspase for the treatment of second-line metastatic pancreatic cancer at ESMO 2017 Congress and met with the U.S. Food & Drug Administration (FDA) to discuss plans for a proposed pivotal Phase 3 trial Resubmitted Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for eryaspase (GRASPA®) for the treatment of patients with relapsed or refractory (R/R... 
 Printer Friendly Version
06-Nov-2017ERYTECH Announces Launch of Proposed Global Offering and NASDAQ Listing
LYON, France--(BUSINESS WIRE)--Nov. 6, 2017-- Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP) (ADR: EYRYY) (“ERYTECH” or the "Company") (Paris:ERYP) (ADR:EYRYY) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced its intention to issue and sell, subject to market and other conditions, approximately $125 million corresponding... 
 Printer Friendly Version
10-Oct-2017ERYTECH Announces Resubmission of European Marketing Authorization Application for GRASPA in Acute Lymphoblastic Leukemia
LYON, France--(BUSINESS WIRE)--Oct. 10, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has resubmitted to the European Medicine Agency (EMA) its Marketing Authorization Application (MAA) for eryaspase (GRASPA®) for the treatment of patients with relapsed or... 
 Printer Friendly Version
06-Oct-2017ERYTECH Files Registration Statement for Proposed Initial Public Offering in the United States
LYON, France--(BUSINESS WIRE)--Oct. 6, 2017-- ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP) (“ERYTECH”), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its American ... 
 Printer Friendly Version
06-Oct-2017Erytech: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –September 30, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Oct. 6, 2017-- Regulatory News: Erytech (Paris:ERYP) (ADR:EYRYY): Date   Total of shares composing the share capital   Total of brut(1) voting righ... 
 Printer Friendly Version
28-Sep-2017ERYTECH Reports Determination of the Recommended Pivotal Phase 3 Dose of eryaspase in its U.S. Phase 1 Study in First Line Adult ALL
Dose of 100 U/kg, which is the same dose used in other studies with eryaspase in adult acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and metastatic pancreatic cancer patients, was recommended for further evaluation of eryaspase in pivotal study in first line adult ALL LYON, France--(BUSINESS WIRE)--Sep. 28, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a clinical-stage biopha... 
 Printer Friendly Version
12-Sep-2017ERYTECH to Present at Morgan Stanley Global Healthcare Conference
LYON, France--(BUSINESS WIRE)--Sep. 12, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR: EYRYY) (Euronext Paris - ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen, Chairman and Chief Executive Officer, will present at the 15th Annual Morgan Stanley Global Healthcare Conference on September 13th, 2017... 
 Printer Friendly Version
11-Sep-2017ERYTECH Reports First Half 2017 Financial Results and Provides Business Update
Conference call and webcast scheduled for Tuesday, September 12th at 02:30 pm CEST/08:30 am EDT Positive final results from Phase 2b study of eryaspase (GRASPA®) for the treatment of metastatic pancreatic cancer presented at the European Society for Medical Oncology (ESMO) 2017 Congress Meeting with the U.S. Food and Drug Administration (FDA) to seek guidance for further clinical development of eryaspase in panc... 
 Printer Friendly Version
08-Sep-2017ERYTECH Announces Positive Full Results from Phase 2b Study of Eryaspase in Combination with Chemotherapy for Treatment of Metastatic Pancreatic Cancer in Second-Line
Full data demonstrates statistically significant improvement in both overall survival and progression-free survival for eryaspase as second-line treatment of metastatic pancreatic cancer Data to be presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid (September 8-12) Meeting with U.S. FDA upcoming to discuss the design of Phase 3 study Company to host Investor &... 
 Printer Friendly Version
06-Sep-2017ERYTECH to Host Second Quarter 2017 Conference Call and Business Update
LYON, France--(BUSINESS WIRE)--Sep. 6, 2017-- Regulatory News: ERYTECH (Paris:ERYP) (ADR:EYRYY), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a Second Quarter 2017 conference call and webcast on Tuesday, September 12, 2017, at 2:30 PM CET/8:30 AM EST to discuss operational highlights. The call ... 
 Printer Friendly Version
06-Sep-2017Erytech: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –August 31st, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Sep. 6, 2017-- Regulatory News: Erytech (Paris:ERYP) (ADR:EYRYY): Date   Total of shares composing the share capital   Total of brut(1) voting righ... 
 Printer Friendly Version
01-Sep-2017ERYTECH to Present Pre-Clinical Data at the 13th International Congress of Inborn Errors of Metabolism
Two abstracts accepted for poster presentation Presentations highlight pre-clinical data on the use of ERYCAPS® technology platform for the treatment of metabolic disorders LYON, France--(BUSINESS WIRE)--Sep. 1, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug s... 
 Printer Friendly Version
31-Aug-2017ERYTECH to Present Full Results for Phase 2b Trial of eryaspase in Pancreatic Cancer at ESMO 2017
Company to host Investor & Analyst Event with live webcast, Monday, September 11, 6:15 p.m. CEST/12:15 p.m. EDT LYON, France--(BUSINESS WIRE)--Aug. 31, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present the full data... 
 Printer Friendly Version
04-Aug-2017ERYTECH Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –July 31st, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Aug. 4, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment C ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
 Printer Friendly Version
12-Jul-2017ERYTECH Announces Collaboration with Queen’s University to Advance its Product Candidate for Rare Metabolic Disorders
LYON, France--(BUSINESS WIRE)--Jul. 12, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into a research collaboration with Queen’s University in Canada to advance the preclinical development of ERYTECH’s eryminase program specifically for... 
 Printer Friendly Version
04-Jul-2017ERYTECH Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –May 31st, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Jul. 4, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment C ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
 Printer Friendly Version
07-Jun-2017ERYTECH Pharma: Annual General Meeting of June 27, 2017
Availability of documents related to the annual general meeting LYON, France--(BUSINESS WIRE)--Jun. 7, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), the French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announced today the modalities for making available the documents for the Annual General Meeting of June 27, 2017. ... 
 Printer Friendly Version
05-Jun-2017ERYTECH Pharma: Information related to total number of voting rights and shares composing the share capital –May 31st, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Jun. 5, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment C ISIN Code : FR0011471135 website : www.erytech.com     ... 
 Printer Friendly Version
18-May-2017ERYTECH Provides Business Update and Financial Highlights For Q1 2017
Conference call and webcast on Friday, May 19th at 15:00 pm CET/09:00 am EDT Reported positive Phase 2b data in metastatic Pancreatic Cancer for eryaspase, demonstrated significant improvement in both progression-free survival (PFS) and overall survival (OS) Launched an investigator-initiated Phase 2 study of eryaspase (GRASPA®) in Acute Lymphoblastic Leukemia (ALL) Presented promising pr... 
 Printer Friendly Version
17-May-2017Erytech to Hold Q1 2017 Business Update Conference Call on May 19th, 2017
LYON, France--(BUSINESS WIRE)--May 17, 2017-- Regulatory News: ERYTECH (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company developing innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it will release its financial results and business update for the quarter ended March 31, 2017 on Thursday, May 18, 2017 aft... 
 Printer Friendly Version
05-May-2017Erytech: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – 30 April 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--May 5, 2017-- Regulatory News: Erytech (Paris:ERYP) (ADR:EYRYY): Date   Total of shares composing the share capital   Total of brut(1) voting right... 
 Printer Friendly Version
04-Apr-2017ERYTECH Announces Launch of Investigator-Initiated Phase 2 Study of eryaspase (GRASPA®) for ALL
LYON, France--(BUSINESS WIRE)--Apr. 4, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) a French clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the launch of an investigator-initiated study to evaluate eryaspase, also known by the trade name GRASPA®, in patients with acute lymphoblastic leukemia (ALL). The study wil... 
 Printer Friendly Version
04-Apr-2017Erytech: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – March 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Apr. 4, 2017-- Regulatory News: Erytech (Paris:ERYP) (ADR:EYRYY): Date   Total of shares composing the share capital   Total of brut(1) voting ri... 
 Printer Friendly Version
03-Apr-2017ERYTECH Makes Its 2016 Reference Document Available
LYON, France--(BUSINESS WIRE)--Apr. 3, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed on March 31, 2017 with the “Autorité des Marchés Fi... 
 Printer Friendly Version
27-Mar-2017ERYTECH Reports Positive Phase 2b Data for eryaspase for the Treatment of Metastatic Pancreatic Cancer
Conference call and webcast on Tuesday, March 28th at 14:30 pm CET/08:30 am EDT Primary progression-free survival (PFS) and overall survival (OS) endpoints met in patients with low asparagine synthetase (ASNS) Statistically significant improvement of OS and PFS in the entire patient population LYON, France--(BUSINESS WIRE)--Mar. 27, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERY... 
 Printer Friendly Version
23-Mar-2017ERYTECH Collaborates with Fox Chase Cancer Center to Advance Its Platform in the Field of Rare Metabolic Disorders
LYON, France--(BUSINESS WIRE)--Mar. 23, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into a research collaboration with Fox Chase Cancer Center (FCCC) to advance the pre-clinical development of the Company’s erymethionase program for h... 
 Printer Friendly Version
20-Mar-2017ERYTECH Presents New Preclinical Anti-Tumor Data on Erymethionase at AACR 2017
LYON, France--(BUSINESS WIRE)--Mar. 20, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced the presentation of new anti-tumor data supporting the Company’s preclinical product e... 
 Printer Friendly Version
07-Mar-2017ERYTECH to Present Preclinical Results Supporting Immunotherapy Potential of ERYMMUNE Platform at Two Upcoming Medical Meetings
LYON, France--(BUSINESS WIRE)--Mar. 7, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced the presentation of encouraging preclinical data supporting the Company’s ERYMMUNE prog... 
 Printer Friendly Version
02-Mar-2017ERYTECH Provides Business Update and Reports Financial Results for Full Year 2016
Conference call and webcast on Friday, March 3rd at 15:00 pm CET/09:00 am EST Activities for resubmission of European Marketing Authorization Application (MAA) for eryaspase (GRASPA) in relapsed and refractory acute lymphoblastic leukemia (ALL)ongoing after withdrawal in November 2016; resubmission targeted in Q3 2017 Patient enrollment completed in Phase 2 study of eryaspase in pancreatic cancer; top-li... 
 Printer Friendly Version
28-Feb-2017ERYTECH to Hold Business Update and 2016 Financial Results Conference Call on March 3rd, 2017
LYON, France--(BUSINESS WIRE)--Feb. 28, 2017-- Regulatory News: ERYTECH (Paris:ERYP) (ADR:EYRYY) :, the clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it will release its financial results and business update for the year ended December 31, 2... 
 Printer Friendly Version
17-Jan-2017ERYTECH Presents New Preclinical Data on ERY-MET at the 2017 ASCO GI Symposium
LYON, France--(BUSINESS WIRE)--Jan. 17, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs (the "Company"), today announced new data supporting the second Company’s product candidate ERY-MET will be presented at the 2017 Gastrointe... 
 Printer Friendly Version
06-Jan-2017Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – December 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Jan. 6, 2017-- Regulatory News: Erytech Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
 Printer Friendly Version
Top